District of Columbia: Dupixent (dupiluma… | DrugsMonitor.com

Dupixent (dupilumab) litigation (DC) District of Columbia focus: docket-era primer, deadlines, case review—not legal advice.

dupilumab, atopic dermatitis, asthma, ocular surface disease, keratitis, vision injury, District of Columbia